Cargando…

H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer

Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only. Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance. Studies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorin, Vladimir, Ohana, Patricia, Gallula, Jennifer, Birman, Tatiana, Matouk, Imad, Hubert, Ayala, Gilon, Michal, Hochberg, Avraham, Czerniak, Abraham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scholarly Research Network 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371723/ https://www.ncbi.nlm.nih.gov/pubmed/22701803 http://dx.doi.org/10.5402/2012/351750

Ejemplares similares

Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report
por: Mizrahi, Aya, et al.
Publicado: (2010)

Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences
por: Mizrahi, Aya, et al.
Publicado: (2009)

The Increasing Complexity of the Oncofetal H19 Gene Locus: Functional Dissection and Therapeutic Intervention
por: Matouk, Imad, et al.
Publicado: (2013)

The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision
por: Matouk, Imad J., et al.
Publicado: (2015)

The H19 Long non-coding RNA in cancer initiation, progression and metastasis – a proposed unifying theory
por: Raveh, Eli, et al.
Publicado: (2015)

The non-coding RNAs of the H19-IGF2 imprinted loci: A focus on biological roles and therapeutic potential in Lung Cancer
por: Matouk, Imad J, et al.
Publicado: (2015)

Use of H19 Gene Regulatory Sequences in DNA-Based Therapy for Pancreatic Cancer
por: Scaiewicz, V., et al.
Publicado: (2010)

A phase 1/2a, dose-escalation, safety, pharmacokinetic, and preliminary efficacy study of intraperitoneal administration of BC-819 (H19-DTA) in subjects with recurrent ovarian/peritoneal cancer
por: Lavie, Ofer, et al.
Publicado: (2017)

Aerosolized BC-819 Inhibits Primary but Not Secondary Lung Cancer Growth
por: Hasenpusch, Günther, et al.
Publicado: (2011)

The H19 Non-Coding RNA Is Essential for Human Tumor Growth
por: Matouk, Imad J., et al.
Publicado: (2007)

Gemcitabine Combination Nano Therapies for Pancreatic Cancer
por: Samanta, Kamalika, et al.
Publicado: (2019)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Gemcitabine‑fucoxanthin combination in human pancreatic cancer cells
por: Lu, Jun, et al.
Publicado: (2023)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma
por: Gong, Dao-Jun, et al.
Publicado: (2013)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
por: Huang, Jun-Hao, et al.
Publicado: (2023)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Li, Doudou, et al.
Publicado: (2015)

Expression of the H19 Oncofetal Gene in Premalignant Lesions of Cervical Cancer: A Potential Targeting Approach for Development of Nonsurgical Treatment of High-Risk Lesions
por: Feigenberg, Tomer, et al.
Publicado: (2013)

Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison
por: Sultana, Asma, et al.
Publicado: (2008)

Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice
por: Selvanesan, Benson Chellakkan, et al.
Publicado: (2020)

Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine
por: Emamzadeh, Mina, et al.
Publicado: (2021)

Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine
por: Wooten, David J., et al.
Publicado: (2022)

Novel Strategy with Gemcitabine for Advanced Pancreatic Cancer
por: Komori, Shuji, et al.
Publicado: (2011)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

Gemcitabine plus S-1 for metastatic pancreatic cancer
por: Zhu, Hong, et al.
Publicado: (2018)

Barriers and opportunities for gemcitabine in pancreatic cancer therapy
por: Beutel, Alica K., et al.
Publicado: (2023)

Determinants of gemcitabine response in pancreatic cancer: are we there?
por: Fitzpatrick, Orla M., et al.
Publicado: (2023)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine
por: Binz, Eike, et al.
Publicado: (2017)

Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma
por: ZHAO, XIN, et al.
Publicado: (2013)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

Astaxanthin inhibits gemcitabine-resistant human pancreatic cancer progression through EMT inhibition and gemcitabine resensitization
por: Yan, Tao, et al.
Publicado: (2017)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ns9u2rhrpvicdbs8h832aql2dp